The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?

Di Giacomo, Anna Maria; Lahn, Michael; Eggermont, Alexander MM; Fox, Bernard; Ibrahim, Ramy; Sharma, Padmanee; Allison, James P.; Maio, Michele

doi:10.1016/j.ejca.2023.113501

European Journal of Cancer

2024

DOI: 10.1016/j.ejca.2023.113501

|View full text |Cite

The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?

Anna Maria Di Giacomo,

Michael Lahn,

Alexander MM Eggermont

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Shen,

Hong,

Huang

et al. 2024

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Shen,

Hong,

Huang

et al. 2024

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas

Roskoski

2024

Pharmacological Research

View full text Add to dashboard Cite

Targeting T regulatory (T_reg) cells in immunotherapy-resistant cancers

Spiliopoulou,

Kaur,

Hammett

et al. 2024

Cancer Drug Resist

Self Cite

View full text Add to dashboard Cite

Primary or secondary (i.e., acquired) resistance is a common occurrence in cancer patients and is often associated with high numbers of T regulatory (Treg) cells (CD4+CD25+FOXP3+). The approval of ipilimumab and the development of similar pharmacological agents targeting cell surface proteins on Treg cells demonstrates that such intervention may overcome resistance in cancer patients. Hence, the clinical development and subsequent approval of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) targeting agents can serve as a prototype for similar agents. Such new agents aspire to be highly specific and have a reduced toxicity profile while increasing effector T cell function or effector T/T regulatory (Teff/Treg) ratio. While clinical development with large molecules has shown the greatest advancement, small molecule inhibitors that target immunomodulation are increasingly entering early clinical investigation. These new small molecule inhibitors often target specific intracellular signaling pathways [e.g., phosphoinositide-3-kinase delta (PI3K-δ)] that play an important role in regulating the function of Treg cells. This review will summarize the lessons currently applied to develop novel clinical agents that target Treg cells.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?

Cited by 3 publications

References 103 publications

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas

Targeting T regulatory (T_reg) cells in immunotherapy-resistant cancers

Contact Info

Product

Resources

About

The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?

Cited by 3 publications

References 103 publications

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas

Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers

Contact Info

Product

Resources

About

Targeting T regulatory (T_reg) cells in immunotherapy-resistant cancers